Dissecting the Urokinase Activation Pathway Using Urokinase-Activated Anthrax Toxin
Anthrax toxin is a three-part toxin secreted by Bacillus anthracis , consisting of protective antigen (PrAg), edema factor (EF), and lethal factor (LF). To intoxicate host mammalian cells, PrAg, the cell-binding moiety of the toxin, binds to cells and is then proteolytically activated by furin on the cell surface, resulting in the active heptameric form of PrAg. This heptamer serves as a protein-conducting channel that translocates EF and LF, the two enzymatic moieties of the toxin, into the cytosol of the cells where they exert cytotoxic effects. The anthrax toxin delivery system has been well characterized. The amino-terminal PrAg-binding domain of LF (residues 1–254, LFn) is sufficient to allow translocation of fused “passenger” polypeptides, such as the ADP-ribosylation domain of Pseudomonas exotoxin A, to the cytosol of the cells in a PrAg-dependent process. The protease specificity of the anthrax toxin delivery system can also be reengineered by replacing the furin cleavage target sequence of PrAg with other protease substrate sequences. PrAg-U2 is such a PrAg variant, one that is selectively activated by urokinase plasminogen activator (uPA). The uPA-dependent proteolytic activation of PrAg-U2 on the cell surface is readily detected by western blotting analysis of cell lysates in vitro, or cell or animal death in vivo. Here, we describe the use of PrAg-U2 as a molecular reporter tool to test the controversial question of what components are required for uPAR-mediated cell surface pro-uPA activation. The results demonstrate that both uPAR and plasminogen play critical roles in pro-uPA activation both in vitro and in vivo.
- A Prognostic Test to Predict the Risk of Metastasis in Uveal Melanoma Based on a 15-Gene Expression Profile
- The Development of Gene Therapy: From Monogenic Recessive Disorders to Complex Diseases Such as Cancer
- Adenovirus-Mediated Targeted Gene Therapy for Breast Cancer and for Purging Hematopoietic Stem-Cell Sources
- Pathology of Kidney Tumors
- Panhandle PCR Approaches to Cloning MLL Genomic Breakpoint Junctions and Fusion Transcript Sequences
- 免疫磁珠分选后阳性细胞极少的问题
- 华人博士发明单个神经细胞及突触体内标识技术
- 基于细胞的酶联免疫检测实验
- galactosidase assay for cells transfected with pSV- -Galactosidase Vector
- MicroRNA Biogenesis and Cancer